On-platform ultrasound system Invenia™ ABUS

for breast ultrasound imagingB/Welastography

Invenia ABUS 2.0, is the first FDA-approved ultrasound supplemental screening technology specifically designed for detecting cancer in dense breast tissue. Designed for screening Improve breast cancer detection by 35.7 percent over mammography alone1 Remarkable image quality Look differently at dense breast tissue with advanced interpretation tools AI Assistant Helps to detect and characterize breast lesions for clinical confidence Invenia ABUS 2.0 transforms breast care from reactive to proactive, helping to detect breast cancers in dense tissue Approximately 40% of women have dense breasts2, one of the strongest common risk factors for developing breast cancer3. Clinical evidence is growing about the effectiveness of ultrasound for finding small, node-negative, invasive cancers missed by mammography4. Invenia ABUS 2.0 supplemental imaging is designed for the screening environment, specifically for dense breast imaging. Personalized breast care with Invenia ABUS 2.0 for early detection, confident diagnosis, and treatment along the breast care pathway. Dense breast tissue and cancer appear white on a mammogram, potentially camouflaging small cancers. Invenia ABUS 2.0, is specifically designed to help clinicians find cancers that may be hidden on mammography The power of early cancer detection Supplemental screening with Invenia ABUS 2.0 transforms breast care from reactive to proactive. When used in addition to mammography, Invenia ABUS 2.0 can improve breast cancer detection by 35.7 percent over mammography alone5. Women whose breast cancer is detected at an early stage have a 90% or higher survival rate